Hoda Rahmani, MD
Family Medicine · Elkhart, INNPI 1063975332
Payments from drug & device makers
Across 46 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$211
- Novo Nordisk$139
- Pfizer$125
- Procept Biorobotics Corporation$119
- AbbVie$107
- Astellas Pharma US Inc$92
- plus $302 from 8 others
What the payments were for
- Food & beverage$1,095100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $211 |
| Novo Nordisk | 6 | $139 |
| Pfizer | 7 | $125 |
| Procept Biorobotics Corporation | 1 | $119 |
| AbbVie | 5 | $107 |
| Astellas Pharma US Inc | 4 | $92 |
| Lilly USA, LLC | 4 | $70 |
| Exact Sciences | 3 | $41 |
| GSK | 2 | $37 |
| Johnson & Johnson | 1 | $35 |
| Phathom Pharmaceuticals, Inc. | 3 | $35 |
| Mayne Pharma Commercial LLC | 1 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$121
- AquaBeam Robotic System$119
How this compares
$1,095 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $44,799 |
| OzempicSemaglutide | 27 | $25,836 |
| FarxigaDapagliflozin Propanediol | 19 | $24,406 |
| EliquisApixaban | 22 | $16,876 |
| XareltoRivaroxaban | 12 | $14,194 |
| TrulicityDulaglutide | 13 | $11,653 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $8,779 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,944 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,231 |
| Mometasone Furoate | 38 | $3,125 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $2,989 |
| SynthroidLevothyroxine Sodium | 26 | $1,783 |
| Atorvastatin Calcium | 134 | $1,542 |
| Omeprazole | 139 | $1,511 |
| Metoprolol Succinate | 65 | $1,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $44,79935 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $211 | $33,18534 claims |
| Novo NordiskOzempic | $139 | $25,83627 claims |
| PfizerEliquis | $125 | $16,87622 claims |
| Johnson & JohnsonXarelto | $35 | $14,19412 claims |
| Lilly USA, LLCTrulicity | $70 | $11,65313 claims |
| GSKBreo Ellipta | $37 | $6,94412 claims |
| AbbVieSynthroid | $107 | $1,78326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Elkhart
- Vikram MehtaElkhart$24K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.